Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.02 EUR | -3.13% | -2.55% | -19.60% |
Apr. 26 | Valbiotis SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Apr. 03 | Valbiotis: launch of Valbiotis PRO Cholesterol in May | CF |
Sales 2023 | 6.81M 7.38M | Sales 2024 * | 11M 11.92M | Capitalization | 65.48M 70.96M |
---|---|---|---|---|---|
Net income 2023 | -7M -7.59M | Net income 2024 * | -6M -6.5M | EV / Sales 2023 | 9.11 x |
Net cash position 2023 * | 19.83M 21.49M | Net cash position 2024 * | 18.13M 19.65M | EV / Sales 2024 * | 4.3 x |
P/E ratio 2023 * |
-4.44
x | P/E ratio 2024 * |
-4.72
x | Employees | 48 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 95.94% |
1 day | -3.25% | ||
1 week | -2.67% | ||
Current month | -2.31% | ||
1 month | +2.16% | ||
3 months | -2.55% | ||
6 months | -29.81% | ||
Current year | -19.70% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | - | |
Pascal Sirvent
CTO | Chief Tech/Sci/R&D Officer | - | 17-08-31 |
Sébastien Bessy
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Agnès Tixier
BRD | Director/Board Member | - | 19-03-17 |
Laurent Lévy
CHM | Chairman | 53 | 17-02-28 |
Chief Executive Officer | - | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 4.02 | -3.13% | 28 221 |
24-05-23 | 4.15 | -0.24% | 66,160 |
24-05-22 | 4.16 | +0.24% | 43,896 |
24-05-21 | 4.15 | -2.24% | 17,482 |
24-05-20 | 4.245 | +2.91% | 25,895 |
Real-time Euronext Paris, May 24, 2024 at 07:31 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-19.70% | 70.87M | |
+10.79% | 116B | |
+11.65% | 106B | |
-6.20% | 23.89B | |
-3.06% | 21.58B | |
-11.25% | 18.96B | |
-13.41% | 16.33B | |
-40.50% | 16.96B | |
+6.64% | 14.14B | |
+31.84% | 12.02B |
- Stock Market
- Equities
- ALVAL Stock